OBJECTIVE -To examine the long-term association of metabolic syndrome with mortality among those at high risk for cardiovascular disease (CVD).
M
etabolic syndrome is a clustering of major cardiovascular disease (CVD) risk factors. The Adult Treatment Panel III (ATP-III) (1) of the National Cholesterol Education Program defines metabolic syndrome as the occurrence of three or more of the following conditions: low HDL cholesterol, elevated triglycerides, elevated blood pressure, elevated fasting glucose or impaired glucose tolerance, and central adiposity; alternate definitions exist (2-4). Metabolic syndrome prevalence is on average 20 -25% among U.S. adults but varies widely by age, race/ethnicity, adiposity, and definition used (5) (6) (7) (8) (9) (10) (11) (12) (13) . Similar or lower prevalences have been seen in Canadian and European (6,14 -20) and Asian (6, (21) (22) (23) (24) (25) cohorts. Rising obesity and diabetes in the U.S. (26) and elsewhere (27, 28) will likely increase the prevalence of metabolic syndrome (29, 30) .
The metabolic syndrome mortality risk among those with CVD, or elevated CVD risk (e.g., LDL cholesterol), has only been briefly studied. Metabolic syndrome prevalences up to 84% have been found in cohorts with elevated CVD risk or prior CVD (31) (32) (33) (34) (35) (36) (37) . Research examining cardiovascular outcomes following metabolic syndrome (34,38 -43) generally had limited follow-up. We examined the associations of metabolic syndrome and its underlying conditions with 18-year total, CVD, and coronary heart disease (CHD) mortality in men at above-average risk of CHD who were randomized into the Multiple Risk Factor Intervention Trial (MRFIT). The long follow-up and large cohort allowed examination of the association of metabolic syndrome with mortality for specific subgroups and of having additional risk factors such as smoking and elevated LDL cholesterol.
RESEARCH DESIGN AND METHODS

MRFIT procedures
Previous reports detail MRFIT (44 -48) , a primary prevention trial of a CHD mortality intervention among men aged 35-57 years at increased risk but without clinical CHD. At screen 1 (1973) (1974) (1975) (1976) , 361,662 men at 22 clinical centers in 18 U.S. cities were scored for CHD risk (based on serum cholesterol, diastolic blood pressure [DBP] , and cigarette smoking). Men in the top 10 -15% of the risk distribution, but with no history of heart attack, treatment for diabetes, DBP Ն115 mmHg, or serum cholesterol Ն350 mg/dl, were invited to screen 2. Screen 2 excluded men with extreme obesity, clinical evidence of CVD or other serious disease, untreated symptomatic diabetes, diets incompatible with the MRFIT intervention (including excessive alcohol intake), treatment with certain medications (e.g., hypoglycemic or lipid-lowering agents), DBP Ն120 mmHg, or refusal to consider quitting smoking. At screen 3, 12,866 men were randomized to special intervention (SI group; n ϭ 6,428, dietary counseling to lower cholesterol, smoking cessation counseling, and antihypertension medication) or usual care (UC group; n ϭ 6,438, referred to their usual physicians). All participants were asked to return to their clinical center annually for at least 6 years (follow-up Ͼ90% at each) for comprehensive evaluation, risk factor assessment, and medical history update including medications. This study's cohort included 11,490 participants who attended annual visit 6 (1980 -1982) . Of the 1,376 participants who did not, 430 were during-trial decedents. Analyses excluded men missing data for three or more metabolic syndrome conditions (n ϭ 133) or for adjusting variables (n ϭ 407, primarily alcohol use and lipid fractions), leaving 10,950 men. Baseline for this study is annual visit 6.
Definition of metabolic syndrome
Metabolic syndrome at annual visit 6 was defined from ATP-III (1) by three or more conditions including BMI Ն30 kg/m 2 (waist circumference was not measured), triglycerides Ն150 mg/dl, HDL cholesterol Ͻ40 mg/dl, systolic blood pressure (SBP) Ն130 mmHg (or DBP Ն85 mmHg or using antihypertensives), and fasting glucose Ն110 mg/dl (or using insulin or hypoglycemic agents). We counted men on lipid-lowering drugs (n ϭ 26) as meeting the triglycerides and HDL cholesterol criteria, even if their measures while on medication were Ͻ150 and Ն40 mg/dl, respectively.
Data collection
Race/ethnicity, education, and parental histories of CVD (heart attack, hypertension, stroke, or other CHD) and diabetes were self-reported at screening. At annual visit 6, disrobed height and weight were recorded, and 12-h fasting blood samples were centrally analyzed for serum glucose, cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol (49, 50) . Blood pressure was the average of two measurements according to a standard protocol by certified observers (51) . Antihypertensive use was from trial prescription and/or self-report. Participants selfreported cigarette use (usual number smoked per day), alcohol use (number of drinks consumed per week), and physical activity (equal to or more than others their age).
During-trial nonfatal CVD was defined by any of the following: coronary bypass surgery, stroke, clinical myocardial infarction, or silent myocardial infarction on resting electrocardiogram at or before annual visit 6 (49, 52) . Annual visit 6 resting electrocardiogram abnormalities were recorded from any of the following: Q wave findings, ST-segment elevations and depressions, negative T waves, high R waves, conduction defects, frequent ventricular premature beats, complete atrioventricular and bundlebranch block, supraventricular tachycardia, and left axis deviation. Morbidity data were not collected posttrial.
Mortality end point definition
Total, CVD, and CHD mortality were primary end points. For decedents through 31 December 1990, vital status was determined by clinical center staff (through 28 February 1982) or by matching identifying information with National Death Index or Social Security Administration records (53) (54) (55) (56) (57) . Two nosologists coded cause-specific mortality based on death certificates using ICD-9; a third nosologist adjudicated disagreements. For 1991-1999, dates and causes of death were obtained using National Death Index Plus (58 -61). CVD mortality was ICD-9 350 -459 and ICD-10 I00-I99 and CHD mortality was ICD-9 410 -414 and 429.2 and ICD-10 I20-I25.
Statistical methods
Participant characteristics, including prevalences of each metabolic syndrome condition, were summarized by annual visit 6 metabolic syndrome presence or absence. Mortality from annual visit 6 through 1999 was compared between metabolic syndrome groups using ageadjusted death rates.
Multivariate-adjusted proportional hazards models (62) , stratified by clinical center, tested risk associated with metabolic syndrome and with an increasing number of metabolic syndrome conditions. Adjusting variables were SI/UC groups, age, African American or not, years of education, parental histories of CVD and diabetes, during-trial nonfatal CVD event, cigarette smoking status at screening, and annual visit 6 smoking status, cigarettes per day, alcoholic drinks per week, physical activity, fasting total cholesterol, LDL cholesterol, and resting electrocardiogram abnormalities.
Because cholesterol treatment guidelines are written for LDL cholesterol (1), and goals depend on additional risk factors such as smoking, we examined metabolic syndrome mortality risk for prespecified subgroups: age, African American or not, nonfatal CVD event, smoking status, and LDL and total cholesterol levels. We examined the mortality risk independently associated with each metabolic syndrome condition, adjusting for the other conditions. Lastly, we examined the mortality risk associated with having other risk factors in addition to metabolic syndrome, including nonfatal CVD event, smoking, and elevated LDL cholesterol. P values given throughout are two tailed; no adjustments for multiple comparisons were made.
RESULTS
Cohort characteristics
Risk factors were reduced at the end of MRFIT active intervention: average blood pressure after 6 years went from 136/91 mmHg at screening to 124/80 mm/Hg among SI men and from 135/91 to 127/84 mm/Hg among UC men, and average cholesterol went from 240 to 228 mg/dl and from 240 to 233 among SI and UC men, respectively. Neither total nor causespecific mortality differed between SI and UC subjects (45) .
Of 10,950 men, 4,588 (41.9%) had metabolic syndrome at annual visit 6, while 6,362 (58.1%) did not (Table 1) . Metabolic syndrome men were more likely to have a parent with diabetes; were less likely to be African American; had on average fewer years of education and higher glucose, triglycerides, SBP, DBP, total cholesterol, and BMI and lower HDL cholesterol; and rated themselves as less physically active than their peers. Metabolic syndrome men were also less likely to be smokers or drinkers of alcohol and had lower average drinks per week, cigarettes per day, and LDL cholesterol.
Among those with metabolic syndrome, 57.9% had three conditions, 32.3% had four, and 9.9% had all five. Elevated blood pressure, elevated triglycerides, and low HDL cholesterol were most common (many MRFIT participants had elevated blood pressure and/or cholesterol at trial's onset) followed by elevated BMI and elevated glucose, similar for those without metabolic syndrome.
Among those with metabolic syndrome, the most common combination of the three or more conditions was elevated blood pressure, elevated triglyceridess, and low HDL cholesterol, with 29.6%. Those three plus elevated glucose accounted for 13.3%, those three plus elevated BMI accounted for 13.1%, and all five accounted for 9.9%. Each other combination accounted for Ͻ7%.
Mortality associated with metabolic syndrome Median mortality follow-up was 18.4 years, with 3,623 deaths, including 1,745 CVD and 1,218 CHD deaths. Ageadjusted total, CVD, and CHD death rates per 10,000 person-years were higher among those with metabolic syndrome than those without (all log-rank test P Ͻ 0.0001) ( Table 1) .
Proportional hazards models showed highly significant differences between men with and without metabolic syndrome (Table 2) . Multivariate-adjusted hazard ratios (HRs) were 1.21 (95% CI 1.13-1.29), 1.49 (1.35-1.64), and 1.51 (1.34 -1.70) for total, CVD, and CHD mortality, respectively. After further adjustment for annual visit 6 levels of glucose, HDL cholesterol, triglycerides, SBP, and BMI, HRs decreased to 1.11 (1.02- An increasing number of metabolic syndrome conditions was associated with higher mortality, up to CHD mortality more than three times higher for five conditions compared with none (Table 2) . Significant linear trends with number of conditions were observed for total, CVD, and CHD mortality (HR 1.11, 1.23, and 1.24, respectively, all P Ͻ 0.0001). When triglycerides and HDL cholesterol conditions did not incorporate lipid-lowering drug use, 26 men were no longer considered as having metabolic syndrome. Multivariate-adjusted metabolic syndrome HRs were then nearly identical: 1.21 (95% CI 1.13-1.30) for total, 1.49 (1.35-1.65) for CVD, and 1.51 (1.34 -1.70) for CHD mortality.
CVD mortality associated with metabolic syndrome for subgroups The association of metabolic syndrome with CVD mortality did not vary significantly across subgroups for SI/UC group, age, African American or not, nonfatal CVD, smoking, LDL cholesterol, and total cholesterol (Table 3) . Among those with metabolic syndrome, there was little evidence of increased risk at higher LDL or total cholesterol levels ( CVD mortality associated with each metabolic syndrome condition Among men with metabolic syndrome, elevated glucose and low HDL cholesterol were most predictive of CVD mortality (Table 4) , while elevated blood pressure and elevated BMI were less so. (Many MR-FIT participants had elevated blood pressure at trial's onset, and extremely obese men were excluded.) After adjusting for other risk factors and the other conditions, among men with metabolic syndrome, the HR for CVD mortality comparing those with elevated glucose with those without was 1.54 (95% CI 1.34 -1.78), those with low HDL cholesterol to those without was 1.45 (1.18 -1.77), those with elevated BMI to those without was 1.34 (1.17-1.54), those with elevated blood pressure to those without was 1.25 (0.98 -1.58), and those with elevated triglycerides to those without was CONCLUSIONS -Metabolic syndrome in the MRFIT survivors was associated with higher 18-year total, CVD, and CHD mortality even after adjusting for SI/UC group, age, African American or not, education, physical activity, and other CVD risk factors. The association increased with number of metabolic syndrome conditions present, up to total mortality twice as high and CVD and CHD mortality almost three times as high among those with all five conditions compared with those with none. Elevated glucose and low HDL cholesterol were most predictive of CVD mortality among those with metabolic syndrome. In contrast, low HDL cholesterol was not predictive among men without metabolic syndrome. Lastly, mortality among men with metabolic syndrome was higher for smokers with elevated LDL cholesterol, regardless of nonfatal CVD status. Our work is unique for its large sample size and long mortality follow-up but limited by lack of posttrial morbidity, restriction to men, and exclusion of duringtrial decedents. The MRFIT age range and exclusion criteria, such as for severe disease (e.g., cancer) or factors thought likely to interfere with the intervention (e.g., extreme obesity, excessive alcohol consumption), also limit the generalizability. Men randomized to MRFIT were at above-average risk for CHD (47) . Other follow-up studies among high-risk groups have been of shorter duration but have also shown high prevalence of and poor prognosis following metabolic syndrome (32, 34, 39, 40) . Other studies in general populations have found lower prevalence of metabolic syndrome but similarly unfavorable prognosis of metabolic syndrome (38, (41) (42) (43) . Our metabolic syndrome definition was based on ATP-III (1) but included use of certain medications, as done elsewhere (8,14 -16,20,22,24,32,35,39,40) . MR-FIT did not collect waist circumference; we used BMI instead, as done elsewhere (12, 14, 15) . Use of BMI may have resulted in lower estimated effects than waist circumference would have shown because BMI includes total fat mass. Waist circumference reflects visceral fat mass, more directly related to insulin resistance (63) (64) (65) (66) (67) (68) (69) .
Metabolic syndrome has had multiple and changing definitions, indicating the uncertainty about a unifying pathogenesis. This is despite Reaven's (70) assertion that the "basic abnormality leading to all of these changes is resistance to insulinmediated disposal," supported by the significant association of ATP-III-defined metabolic syndrome with measured insulin resistance among healthy adults (71) with high specificity (72) . Nevertheless, in a recent extensive review (73) , the imprecision of the metabolic syndrome definition led the authors to doubt the value of using the syndrome as a marker for CVD risk and to emphasize the importance of treatment of all CVD risk factors. This view is supported by our results showing an increased risk with additional metabolic syndrome conditions, from one condition to the full complement of five, along with a further increase in risk with smoking and elevated LDL cholesterol. In a population study in the U.K., analysis of different ways of combining the conditions of metabolic syndrome showed that this clustering had no greater predictive value beyond the consideration of all of the individual risk factors (74) . This held true in the MRFIT cohort as well when adjusting for trial-averaged risk factors but not for single ascertainment of risk factors. As the utility of metabolic syndrome continues to be debated, Grundy et al. (75) describe metabolic syndrome as a combination of metabolic risk factors and underlying risk factors, which give rise to the metabolic risk factors, and recognize that metabolic syndrome is not a discrete entity known to be caused by a single factor; they emphasize again its strong association with obesity.
The justification for invoking the syndrome (Mitka [76] , quoting Scott Grundy, chair of ATP-III) was to garner attention and action by primary care physicians who had apparently paid scant regard to the admonition for weight reduction promulgated in ATP-II (77).
However, there is real danger that such concentration on a cluster of three of five conditions (unjustified by the additive predictiveness of all five) will distract from the need to address all risk factors including those not part of the five, namely LDL cholesterol and smoking. 
